<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03472014</url>
  </required_header>
  <id_info>
    <org_study_id>POX-MVA-03x</org_study_id>
    <nct_id>NCT03472014</nct_id>
  </id_info>
  <brief_title>Special Access Program IMVAMUNE®</brief_title>
  <official_title>A Special Access Program for the Prophylactic Vaccination With IMVAMUNE® for Personnel Working Directly With or in the Vicinity of Replicating Vaccinia Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bavarian Nordic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bavarian Nordic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prophylactic smallpox vaccination for personnel actively working with or in the vicinity of
      replicating vaccinia virus
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 22, 2010</start_date>
  <completion_date type="Actual">November 14, 2014</completion_date>
  <primary_completion_date type="Actual">November 14, 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seropositivity rate</measure>
    <time_frame>up to 7 weeks</time_frame>
    <description>Seropositivity rate after IMVAMUNE vaccination measured by vaccinia-specific ELISA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seroconversion rate</measure>
    <time_frame>up to 7 weeks</time_frame>
    <description>Seroconversion rate after IMVAMUNE vaccination measured by vaccinia-specific ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody Titer</measure>
    <time_frame>up to 7 weeks</time_frame>
    <description>Geometric Mean Titer after IMVAMUNE vaccination measured by vaccinia-specific ELISA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurence of SAEs</measure>
    <time_frame>up to 37 weeks</time_frame>
    <description>Occurrence, relationship to the investigated vaccine and intensity of any serious AE (SAEs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Possibly, probably or definitely related Grade 3 or 4 AE</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>Occurrence of any Grade 3 or 4 AE possibly, probably or definitely related to the investigated vaccine within 28 days after each vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-serious AEs</measure>
    <time_frame>up to 8 weeks</time_frame>
    <description>Occurrence, relationship to the investigated vaccine and intensity of non-serious AEs within 28 days after each vaccination.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Vaccination</condition>
  <arm_group>
    <arm_group_label>IMVAMUNE®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two subcutaneous vaccinations with 0.5 mL IMVAMUNE® vaccine administered at a 4 week intervals</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMVAMUNE®</intervention_name>
    <description>IMVAMUNE® liquid -frozen, containing 1 x 10E8 TCID50 MVA-BN® per 0.5 mL dose</description>
    <arm_group_label>IMVAMUNE®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects, aged 18-65 years, who will work with or in the vicinity of a
             replicating vaccinia virus and who volunteer for the program. Subjects may be
             vaccinia-naïve or vaccinia-experienced.

          -  Women of child-bearing potential (WOCBP) must have a negative urine pregnancy test
             within 48 hours prior to vaccination.

          -  WOCBP must have used an acceptable method of contraception for at least 30 days prior
             to the first vaccination and must agree to use an acceptable method of contraception
             during the vaccination period until at least 28 days after the last vaccination. A
             woman is considered of child-bearing potential unless post-menopausal or surgically
             sterilized. (Acceptable contraception methods are restricted to barrier contraceptives
             which include Food and Drug Administration (FDA)-approved spermicides, intrauterine
             contraceptive devices, or licensed hormonal products.)

          -  Read, signed and dated Informed Consent Form.

        Exclusion Criteria:

          -  Pregnant or breast-feeding women.

          -  Uncontrolled serious infection i.e., not responding to antimicrobial therapy.

          -  History of or active autoimmune disease. Persons with vitiligo or thyroid disease
             taking thyroid replacement are not excluded.

          -  Known or suspected impairment of immunologic function including, but not limited to,
             clinically significant liver disease; uncontrolled diabetes mellitus; moderate to
             severe kidney impairment or post organ transplant subjects.

          -  History of malignancy, other than squamous cell or basal cell skin cancer, unless
             there has been surgical excision that is considered to have achieved cure.

          -  History of coronary heart disease, myocardial infarction, angina, congestive heart
             failure, cardiomyopathy, stroke or transient ischemic attack, uncontrolled high blood
             pressure, or any other heart condition under the care of a doctor.

          -  History of allergies or reactions to eggs, egg products, or gentamycin.

          -  Having received any vaccinations or planned vaccinations with a live vaccine within 28
             days or a killed vaccine within 14 days prior to or after IMVAMUNE®vaccination.

          -  Chronic administration (defined as more than 6 days) of systemic corticosteroids
             within 30 days of the first planned vaccination.

          -  Use of any investigational or non-registered drug or vaccine other than IMVAMUNE®
             within 30 days preceding the first vaccine dose.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Fujimoto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Palo Alto Medical Foundation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Palo Alto Medical Foundation</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 21, 2018</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

